NCT01862900View on ClinicalTrials.gov

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 27, 2012

Primary Completion Date

May 17, 2016

Study Completion Date

August 15, 2018

Conditions
Metastatic Breast CancerLung MetastasesLiver Metastases
Interventions
BIOLOGICAL

MEDI6469

Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5

Trial Locations (1)

97213

Portland Providence Medical Center, Portland

Sponsors

Collaborators (1)

MedImmune LLC
All Listed Sponsors
collaborator

Robert W. Franz Cancer Center

UNKNOWN

collaborator

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

collaborator

MedImmune LLC

INDUSTRY

lead

Providence Health & Services

OTHER